Brokerages Set Omeros Co. (NASDAQ:OMER) Target Price at $22.50

Shares of Omeros Co. (NASDAQ:OMER - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five brokerages that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $22.50.

A number of brokerages have recently commented on OMER. D. Boral Capital reissued a "buy" rating and set a $36.00 price target on shares of Omeros in a report on Friday, April 11th. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research report on Tuesday, April 1st. Finally, StockNews.com cut shares of Omeros from a "hold" rating to a "sell" rating in a report on Wednesday, April 9th.

Institutional Investors Weigh In On Omeros

A number of institutional investors and hedge funds have recently bought and sold shares of OMER. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Omeros by 3.6% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,831 shares of the biopharmaceutical company's stock worth $314,000 after acquiring an additional 1,110 shares in the last quarter. Truvestments Capital LLC boosted its position in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,669 shares during the period. Tower Research Capital LLC TRC increased its stake in Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock worth $44,000 after purchasing an additional 1,972 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in Omeros by 2.0% during the 4th quarter. Ameriprise Financial Inc. now owns 120,493 shares of the biopharmaceutical company's stock worth $1,190,000 after buying an additional 2,317 shares during the period. Finally, Cerity Partners LLC boosted its holdings in shares of Omeros by 9.9% in the fourth quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company's stock worth $286,000 after buying an additional 2,600 shares during the period. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Trading Down 4.5 %

Omeros stock traded down $0.33 during midday trading on Friday, reaching $7.02. 542,628 shares of the stock traded hands, compared to its average volume of 582,435. The firm has a fifty day moving average price of $7.66 and a two-hundred day moving average price of $8.03. Omeros has a fifty-two week low of $3.00 and a fifty-two week high of $13.60. The firm has a market cap of $407.61 million, a price-to-earnings ratio of -3.04 and a beta of 2.35.

Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $0.08. During the same period in the prior year, the business earned ($0.15) earnings per share. Analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.